# IMCD Group account plan

> IMCD distributes and formulates speciality chemicals and ingredients in over 60 countries, with FY2025 revenue of EUR 4,778.9 million.

## At a glance

IMCD N.V., founded in Rotterdam in 1995 and listed on Euronext Amsterdam since 2014, distributes and formulates speciality chemicals and ingredients for more than 71,000 active customers on behalf of over 3,000 suppliers. It runs an asset-light model: 123 offices and 86 laboratories and technical centres, with physical distribution outsourced to third-party logistics partners. In FY2025 it reported revenue of EUR 4,778.9 million (+1%), operating EBITA of EUR 497.8 million (-6%) and a net result of EUR 217.5 million, with 5,246 employees. The business is organised as a matrix of regional country P&Ls (EMEA, Americas, Asia-Pacific) and eight global Business Groups across Life Science and Industrial markets.

## Business units

- **EMEA** (EUR 2,078.1 million revenue, 43.5% of FY2025 group revenue): Operating companies in Europe, Türkiye, Israel, Egypt, the UAE, Saudi Arabia and Africa, with 33 application laboratories and 2,175 FTE. In the first nine months of 2026 revenue rose 14% to EUR 1,822.8 million and operating EBITA 16% to EUR 210.1 million, helped by the Ferrer Alimentación, TECOM, Tillmanns and Willows Ingredients acquisitions. Andreas Igerl is President EMEA.
- **Americas** (EUR 1,448.5 million revenue, 30.3% of FY2025 group revenue): Operating companies across the United States, Canada and Latin America, with 1,458 FTE; North America made EUR 947.1 million of FY2025 revenue and Latin America EUR 501.4 million. It is the weakest region: nine-month 2026 revenue fell 1% to EUR 1,109.9 million and operating EBITA 10% to EUR 105.2 million, with US coatings and construction demand weak.
- **Asia-Pacific** (EUR 1,252.3 million revenue, 26.2% of FY2025 group revenue): Operating companies in 14 countries from Australia and India to China, Japan and South Korea, with 1,469 FTE. It carries the group's highest EBITA margin, 13.2% in the first nine months of 2026, when revenue rose 8% to EUR 1,031.8 million; recent acquisitions include YCAM, Daoqin, Trichem, Dong Yang FT and Merit Solution.
- **Life Science market segment** (EUR 2,603.8 million FY2025 sales of goods, about 55%): Groups the Pharmaceuticals, Beauty & Personal Care, Food & Nutrition and Home Care I&I Business Groups, which the annual report says have historically been less sensitive to economic fluctuations. Pharmaceuticals is led by Business Group Director John Robinson.
- **Industrial market segment** (EUR 2,162.3 million FY2025 sales of goods, about 45%): Groups Coatings & Construction, Lubricants & Energy, Industrial Solutions and Advanced Materials, a more cyclical segment tied to housing, automotive and oil and gas. Andreas Igerl became Global Director Industrial Business Groups in 2025.

## Strategic priorities

- **Return profit to historical levels**: The CEO's stated ambition is to bring profit indicators back to historical levels after FY2025 operating EBITA fell 6% and the EBITA margin dropped to 10.4% from 11.2%.
- **Organic growth from supplier mandates**: Management reaffirmed medium-term guidance of around 6%-7% organic gross profit growth and reports new supplier mandate wins as suppliers outsource more of their sales organisation.
- **Digital and AI-enabled selling**: IMCD launched its SalesAssistant sales-enablement platform globally in 2025, runs the MyIMCD customer portal on a single ERP/CRM backbone, and is adding a fully automated pre-visit summary for salespeople.
- **Fix the Americas**: Regional management has been strengthened and the US coast-to-coast supplier model is being expanded, after Americas organic EBITA fell 8% in the first nine months of 2026.
- **Selective acquisitions**: IMCD completed seven acquisitions in 2025 adding EUR 319.5 million annualised revenue and three more in 2026, while stating it is not in a rush to close deals.
- **Emissions reduction**: IMCD targets a 60% reduction in absolute Scope 1 and 2 emissions by 2034 from a 2024 baseline and is filing its SBTi near-term targets for validation.

## Latest results

In the first nine months of 2026 revenue rose 8% to EUR 3,965 million (+10% at constant currency), operating EBITA rose 8% to EUR 425 million and the net result reached EUR 211 million. Momentum built through the year: organic gross profit growth went from -4% in Q1 to +7% in Q2 and +10% in Q3, and Q3 operating EBITA grew 18% with 14% organic growth across all segments. Free cash flow rose 12% to EUR 317 million and net debt fell to EUR 1,523.7 million, a leverage of 2.6x. EMEA and Asia-Pacific drove growth while the Americas still declined. IMCD gives no numeric outlook but expects organic operating EBITA growth in 2026.

## Investments and deals

- **2025 acquisitions**: Seven deals in 2025 (YCAM, Daoqin, Ferrer Alimentación, Trichem, TECOM, Apus Quimica, Tillmanns) added EUR 319.5 million annualised revenue; acquisition-related payments were EUR 437.2 million.
- **2026 acquisitions**: Dong Yang FT (Korea, cosmetic ingredients) closed in January 2026, Willows Ingredients (Ireland/UK, food and nutrition) in March 2026, and Merit Solution (Thailand, plastics additives) on 25 August 2026.
- **Laboratories**: Six new or upgraded laboratories opened in 2025, including a Life Science Laboratory hub in Shanghai and a Food & Nutrition lab in Jakarta.
- **Credit facility**: The revolving credit facility was increased by EUR 100 million to EUR 700 million on 27 January 2026.
- **Restructuring**: FY2025 one-off costs of EUR 25.1 million included EUR 14.8 million of restructuring and severance; holding costs were cut 15% to EUR 33.4 million and the back office rationalised for a net saving of about 200 employees.

## Challenges and risks

- **Weak Americas**: The CFO called the Americas outcome disappointing: nine-month 2026 EBITA fell 10% with a 9.5% margin, as North American coatings and construction demand stays weak.
- **Margin pressure from acquisitions**: Gross margin was 24.9% in H1 2026 versus 25.6%, partly because recently acquired companies carry lower margins.
- **Unpredictable demand**: IMCD states that macro-economic and political uncertainty make demand difficult to predict, and customers continue to order just-in-time.
- **Supplier dependency and currency**: Top risks include supplier dependency, where losing a major supplier could be material, and currency volatility rated high likelihood; currency cost EUR 12 million of EBITA in H1 2026.
- **Chinese competition**: Management says competition from China is present in the Americas, without significant change between Q2 and Q3 2026.

## What leadership says

> "It is clear that our partners need us now more than ever" — Marcus Jordan, Chief Executive Officer, First nine months 2026 results conference call, 5 November 2026

> "The third quarter showed sustained business momentum, with healthy free cash flow and 14% organic EBITA growth, with contributions from all regions." — Marcus Jordan, Chief Executive Officer, First nine months 2026 results release, 5 November 2026

> "So far, we have a structure that can cope with more sales than what we have today, thanks to all the digital developments and thanks to the additional salespeople" — Hans Kooijmans, Chief Financial Officer, Half-year 2026 results conference call, 29 July 2026


## Where a supplier can help

- **Sales-enablement and AI tooling**: Tied to the digital and AI-enabled selling priority: SalesAssistant and automated pre-visit summaries show IMCD is investing in tools that make its frontline commercial teams more effective.
- **Commercial excellence in the Americas**: Tied to the Americas challenge: management says the fix is strengthening commercial excellence rather than extra investment, an opening for sales-performance and market-coverage support.
- **Acquisition integration**: Tied to the acquisition programme: ten deals across 2025 and 2026 need integrating onto IMCD's single ERP/CRM backbone, where integration services and data migration help.
- **Laboratory and formulation equipment**: Tied to the laboratory investments: new and upgraded labs and rising formulation projects create demand for lab equipment and technical services.
- **Emissions reporting**: Tied to the emissions-reduction priority: the SBTi filing and a 60% Scope 1 and 2 reduction target call for carbon accounting and energy-efficiency support across offices and labs.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [IMCD N.V. Annual Report 2025](https://a.storyblok.com/f/329380/x/3ba37e7fac/imcd-annual-report-2025.pdf)

Annual report · 2026-03-04

- IMCD N.V. (Rotterdam, founded 1995, listed on Euronext Amsterdam since 2014, AEX member since 2019) is a global partner for the distribution and formulation of speciality chemicals and ingredients: operations in over 60 countries, 123 offices, 86 laboratories and technical centres, 71,000+ active customers, 3,000+ suppliers, 52,000+ products, 5,246 employees.
- FY2025: revenue EUR 4,778.9 million (+1%, +5% at constant currency); gross profit EUR 1,193.5 million (25.0% of revenue); operating EBITA EUR 497.8 million (-6%, -3% at constant currency), margin 10.4% vs 11.2%; net result EUR 217.5 million (-22%); free cash flow EUR 465.2 million (+3%), cash conversion margin 91.4%.
- Three regional reporting segments: EMEA EUR 2,078.1 million revenue (43.5%), Americas EUR 1,448.5 million (30.3%), Asia-Pacific EUR 1,252.3 million (26.2%). All three saw EBITA fall organically (EMEA -5.8%, Americas -9.1%, Asia-Pacific -7.3%).
- Eight Business Groups run as a matrix with country P&Ls: Life Science (Pharmaceuticals, Beauty & Personal Care, Food & Nutrition, Home Care I&I) sold EUR 2,603.8 million and Industrial (Coatings & Construction, Lubricants & Energy, Industrial Solutions, Advanced Materials) EUR 2,162.3 million.
- Growth by acquisition: seven deals in 2025 (YCAM, Daoqin, Ferrer Alimentación, Trichem, TECOM, Apus Quimica, Tillmanns) adding EUR 319.5 million annualised revenue; Dong Yang FT closed January 2026 and Willows Ingredients signed February 2026. Acquisition-related payments EUR 437.2 million; net debt EUR 1,551.6 million, adjusted leverage 2.8x.
- Leadership change: Marcus Jordan (27 years at IMCD, ex-COO and President Americas) succeeded Valerie Diele-Braun as CEO in April 2025; long-time CFO Hans Kooijmans to be succeeded by internal candidate Floris Lagerwerf in 2027. Executive Committee cut to three members beside the Management Board.
- Strategy rests on six pillars (people, portfolio expansion, commercial, operational and digital excellence, sustainability); digital investment includes the SalesAssistant sales-enablement platform launched globally in 2025, MyIMCD customer portal and a single ERP/CRM backbone with AI tools.
- Cost and restructuring: EUR 25.1 million one-off costs, of which EUR 14.8 million restructuring and severance; holding costs cut 15% to EUR 33.4 million. Dividend proposal cut to EUR 1.81 per share (from EUR 2.15).
- Top risks: decline in customer demand, supplier dependency, acquisition/integration risk, dependency on key personnel, cybercrime/ICT continuity; currency volatility rated high likelihood. Outlook 2026 gives no figure: macro and political uncertainty make demand "difficult to predict".

### [IMCD half-year 2026 results and condensed consolidated interim financial statements](https://ml-eu.globenewswire.com/Resource/Download/71fff627-feea-4146-a0b4-1594c289a44e)

Interim report · 2026-07-29

- H1 2026 (to 30 June): revenue EUR 2,638 million (+7%, +11% at constant currency), gross profit EUR 658 million (+7% at constant currency), operating EBITA EUR 285 million (+4%, +8% at constant currency), net result EUR 142 million (+10%).
- Recovery through the half: Q2 operating EBITA +16% with organic growth in all regions (+11%); Q2 revenue +13%.
- Free cash flow up 29% to EUR 222 million; cash conversion margin 76.2% (61.4%). Net debt EUR 1,559.6 million, leverage 2.8x.
- EMEA was the engine: revenue +15% to EUR 1,225.0 million, EBITA +15% to EUR 142.9 million (organic +7%), now 46.4% of group revenue.
- Americas weak: revenue -4% to EUR 736.8 million, EBITA -16% to EUR 70.0 million (organic -12%), margin 9.5%.
- Asia-Pacific: revenue +6% (+14% at constant currency, organic +7%), EBITA EUR 89.1 million, margin 13.2%.
- Gross margin fell to 24.9% (25.6%), partly because acquired companies carry lower margins.
- M&A: Dong Yang FT (Korea) and Willows Ingredients (Ireland/UK) completed, agreement to buy Merit Solution (Thailand, plastics additives). RCF raised to EUR 700 million.
- No numeric outlook; CEO Marcus Jordan: "We have had a positive first half of the year".

### [IMCD reports EBITA of EUR 425 million (+8%) in the first nine months of 2026](https://ml-eu.globenewswire.com/Resource/Download/c5d61f6d-f040-4b94-ab34-86a2dc0072ba)

Interim report · 2026-11-05

- First nine months 2026: revenue EUR 3,965 million (+8%, +10% at constant currency), gross profit EUR 991 million (+9% at constant currency), operating EBITA EUR 425 million (+8%, +11% at constant currency), net result EUR 211 million (+20% at constant currency).
- Q3 2026 accelerated: operating EBITA +18% with 14% organic growth and organic growth in all segments; Q3 revenue +10% (organic +6%), gross profit +14% (organic +10%).
- Free cash flow up 12% to EUR 317 million; cash conversion margin 73.0%; net debt down to EUR 1,523.7 million, leverage 2.6x.
- EMEA (EUR 1,822.8 million revenue, EBITA EUR 210.1 million, +16%) and Asia-Pacific (EUR 1,031.8 million, EBITA EUR 136.3 million, +11%, organic +10%) drove growth.
- Americas still declining: revenue EUR 1,109.9 million (-1%), EBITA EUR 105.2 million (-10%, organic -8%), margin 9.5%.
- Merit Solution (Thailand) completed on 25 August 2026.
- Outlook upgraded to a statement: IMCD "expects organic operating EBITA growth in 2026".

### [IMCD 2026 first nine months results conference call (transcript)](https://stockanalysis.com/quote/ams/IMCD/transcripts/665676-q3-2026/)

Executive talk · Marcus Jordan, Chief Executive Officer · 2026-11-05

- Last call of CFO Hans Kooijmans (his 50th), who retires at the end of 2026; Floris Lagerwerf succeeds him.
- CEO Marcus Jordan: "It is clear that our partners need us now more than ever", visible in formulation projects through IMCD's labs and new supplier mandates.
- 9M 2026 gross profit EUR 991 million (+9% at constant currency), EBITA EUR 425 million (+11%), free cash flow EUR 317 million; Q3 organic EBITA +14%.
- Organic gross profit growth went from -4% in Q1 to +7% in Q2 and +10% in Q3.
- Pricing back to "more normal pricing behavior" after Q2 supplier price increases; customers still order just-in-time.
- Kooijmans: "The outcome in the Americas is disappointing"; Jordan says the strengthened regional management makes him "cautiously optimistic", and the US coast-to-coast supplier model is gaining traction.
- Medium-term guidance of around 6%-7% organic gross profit growth reaffirmed; leverage of 2.6x gives M&A firepower, but IMCD is "Not being in a rush to close deals."
- No impairments expected; year-end cash conversion guided "somewhere around a high 80% or a low 90% number"; AI investment to drive effectiveness, efficiency gains longer term.

### [IMCD 2026 half-year results conference call (transcript)](https://stockanalysis.com/quote/ams/IMCD/transcripts/549676-q2-2026/)

Executive talk · Marcus Jordan, Chief Executive Officer · 2026-07-29

- H1 2026 call (29 July 2026), CEO Marcus Jordan and CFO Hans Kooijmans: gross profit EUR 658 million (+7% at constant currency), EBITA EUR 285 million (+8%), free cash flow EUR 222 million.
- Most suppliers raised prices in Q2, much less on specialties than on semi-specialties; IMCD was "particularly careful and responsible when passing on price increases".
- Pre-buying at the start of Q2 was limited; customers "learned valuable lessons from post-COVID when they overstocked".
- Organic gross profit -4% in Q1 then +7% in Q2; EBITA organic -9% then +11%; EMEA EBITA organic +20% in Q2.
- Supplier mandate wins discussed proactively for the first time; suppliers "are having a pretty tough time" and are outsourcing more.
- Americas lags: weak US coatings and construction; regional management strengthened.
- AI: SalesAssistant extended and "a fully automated pre-visit summary for our salespeople"; a global people director added to the Executive Committee.
- Kooijmans: back office rationalised (net about 200 fewer employees), no organic increase in own costs; "we have a structure that can cope with more sales than what we have today".
- M&A: about EUR 50 million spent in H1; "We are definitely not being impatient".

## Questions about IMCD Group

### What does IMCD do?

IMCD distributes and formulates speciality chemicals and ingredients, connecting over 3,000 suppliers with more than 71,000 active customers. It provides technical advice and formulation support through 86 laboratories and technical centres while outsourcing physical logistics.

### What is IMCD's revenue?

IMCD reported FY2025 revenue of EUR 4,778.9 million and operating EBITA of EUR 497.8 million. In the first nine months of 2026 revenue was EUR 3,965 million, up 8%.

### How many employees does IMCD have?

IMCD had 5,246 employees at the end of 2025 and an FTE count of 5,264 at the end of September 2026.

### Who leads IMCD?

Marcus Jordan has been CEO since April 2025. Hans Kooijmans, CFO since 1996, retires at the end of 2026 and is succeeded by Floris Lagerwerf.

### What is IMCD's strategy?

IMCD aims to lead in every market its eight Business Groups serve, growing organically through supplier partnerships and technical solutions and through selective acquisitions, under six pillars: people, portfolio expansion, commercial, operational and digital excellence, and sustainability.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
